In a phase I trial with GDC-0941, a heavily treated ovarian cancer patient with PIK3CA amplification experienced disease stabilization for 4 months with significant pharmacodynamic changes [37]. The gene discussed is PIK3CA; the disease is ovarian carcinoma.